Purple Biotech Ltd.: Purple Biotech: closing of up to $18M

Purple Biotech Ltd.: Purple Biotech: closing of up to $18M

Rehovot, Israel — September 2, 2025 — Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biotechnology company specializing in first-in-class therapies for overcoming tumor immune evasion and drug resistance, has successfully closed its public offering. The company announced that it has raised approximately $6 million upfront, with potential additional gross proceeds of up to $12 million from the exercise of short-term warrants [1].

The public offering, which was priced at $1.00 per share, included the issuance of 5,999,999 American Depositary Shares (ADSs) and short-term warrants to purchase up to 11,999,998 ADSs. The short-term warrants have an exercise price of $1.00 per ADS and are exercisable immediately upon issuance, with an expiration date twenty-four months from the date of issuance [1].

The net proceeds from this offering will be used to fund the development of Purple Biotech's oncology therapeutic candidates, including CAPTN-3, CM24, and NT219, as well as for general working capital and corporate purposes [1]. The company's oncology pipeline includes CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, and CM24, a humanized monoclonal antibody that blocks CEACAM1, a target for multiple cancer indications [1].

Purple Biotech's corporate headquarters are located in Rehovot, Israel. For more information, please visit https://purple-biotech.com [1].

References:

[1] https://www.globenewswire.com/news-release/2025/09/04/3144628/0/en/Purple-Biotech-Announces-Pricing-of-Up-To-18-Million-Public-Offering.html